Risk factors
Tarsus Pharmaceuticals (TARS) risk factors
Item 1A of every Tarsus Pharmaceuticals, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors72 risks12 new6 dropped18 reworded
Tarsus faces heightened regulatory scrutiny on direct-to-consumer advertising following FDA untitled letters.
Filed Feb 23, 2026 - FY2024 10-K risk factors66 risks
Tarsus relies heavily on the commercial success of its sole approved product, XDEMVY, for Demodex blepharitis. The company faces significant financial risks requiring additional capital, intellectual property challenges, and strict regulatory oversight across manufacturing and clinical trials.
Filed Feb 25, 2025